Recall of Kidney Dialysis Anemia Drug | Omontys

Affymax Inc. and Takeda Pharmaceutical recalled all lots of their Omontys brand peginesatide anti-anemia drug. The recall follows post-marketing reports of serious hypersensitivity reactions in many users, including anaphylaxis and death.

Fatal reactions in about 0.02 percent of patients following the first intravenous dose of Omontys. That is a small amount on one level; on another, 25,000 people have taken the drug.